Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | multiple myeloma |
| ICD-0-3 | C42.1 |
| Methods | Microarray, qPCR, RIP, Dual Luciferase reporter assay |
| Sample | cell lines (ARP-1, LP-1) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 was downregulated in MM patients, which was linked with tumor progression. MEG3, acting as an endogenous competitive RNA, could contend with miR-181a to inhibit tumor progression. the expression of MEG3 is downregulated in MM patients and correlated with poor prognosis. Accordingly, the CCK-8 proliferation assay manifested that overexpression of miR-181a exerted more evident cell proliferation, while silencing miR-181a expression inhibited cell growth. |
| Pubmed ID | 30134227 |
| Year | 2018 |
| Title | Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate HOXA11 Expression by Sponging miR-181a in Multiple Myeloma. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for multiple myeloma | OMIM COSMIC |